Markets
markets

Tariffs push prices up and profits down at Smucker

JM Smucker fell in premarket trading after its fiscal Q1 results undershot Wall Street expectations.

The impact of Trump administration tariffs on the company’s retail coffee business — which includes brands like Folgers, Dunkin’, and Cafe Bustelo and is its largest revenue producer — was the issue.

Smucker was able to pass some of the tariffs on imports from coffee-producing countries like Vietnam and Brazil along to shoppers in the form of higher prices. In fact, the coffee unit’s sales of $717.2 million, up 15%, were better than Wall Street expected.

But price hikes didn’t cover all of the tariff bill, and the company swallowing a portion of those higher costs contributed to a 22% tumble in the coffee segment’s profits.

Smucker was able to pass some of the tariffs on imports from coffee-producing countries like Vietnam and Brazil along to shoppers in the form of higher prices. In fact, the coffee unit’s sales of $717.2 million, up 15%, were better than Wall Street expected.

But price hikes didn’t cover all of the tariff bill, and the company swallowing a portion of those higher costs contributed to a 22% tumble in the coffee segment’s profits.

More Markets

See all Markets
markets

Analysts generally like what they heard from Oracle, but shares are down

The big news out from the Oracle AI World conference was broadly positive: that margins on cloud infrastructure can be as high as 35%, and that the company predicts $166 billion in infrastructure revenue by 2030.

And in the wake of that news, today UBS raised its price target for Oracle shares to $380 from $360, saying they are undervalued.

But investors appear to have some concerns about Oracle’s huge capex plans, which are fueled by huge AI infrastructure deals with OpenAI and Meta, as shares dropped over 7% in Friday trading.

Analysts have pointed to Oracle’s high cash burn as it pursues its AI build-out and potential financing needs as flies in the ointment that could blunt the impact of the companys strong longer-term growth forecasts.

On Friday, Jeffries analysts wrote:

Questions remain about ORCLs capex requirements to meet growing demand, as there was no forward-looking commentary on capex at the Analyst Day. Capex will need to ramp in line with [Oracle cloud infrastructure] revenue growth, raising concerns about ORCLs financing options to support this expansion.

However, if thats the reason why the stock is getting hit today, it would mark a distinct change in how investors are evaluating the AI trade. Companies have tended to be increasingly rewarded for their aggressive capex commitments to enhance the boom, based on optimism that investments in this would-be revolutionary technology will bear fruit.

Fridays dip comes on the back of a strong run leading up to the yesterdays investor conference, fueled by a flurry of AI headlines. Oracle shares have gained over 18% in the past three months and more than 70% so far this year, well outpacing the Nasdaqs approximately 7% and 16% rise over the same time periods.

markets

AST SpaceMobile drops after Barclays cuts rating to “underweight”

AST SpaceMobile, which provides cellular services from space, dove in early trading after Barclays analysts cut their rating on the shares to “underweight” (essentially a sell) from “overweight” (or a buy), citing “excessive” valuation on the still money-burning company. The fact that analysts went from “buy” to “sell” — with no momentary stop at a “hold” or “neutral” rating — makes it a fairly rare “double downgrade.”

They wrote:

“Valuation has run ahead of fundamentals... In our last update, we increased our price target from $38 to $60 as we took a more constructive view on pricing; we found it supportive that TMUS/Starlink launched a text only service for $10 per month and believe that AST products which will be richer (text, call, broadband) could see higher prices points. Since then the stock price has doubled from $48 to $95.7.”

With the shares up almost 120% over the last month through Thursday, and a price-to-forward-sales ratio of 140x — the Nasdaq Composite is around 5x — the stock might be due for a cooling-off period.

'There's nothing perfect in this world of growing apples.' Extreme weather could complicate future harvests.

The remarkable rise of the Honeycrisp and Cosmic Crisp apples

When it comes to apples, America cannot get enough of the crunch factor.

markets

Novo, Lilly fall after Trump says “the fat loss drug” will go down in price

Novo Nordisk and Eli Lilly slipped after the bell on Thursday, and continued to trade lower in the premarket session Friday, after President Trump told reporters on Thursday that “the fat loss drug” will go down in price.

Trump said GLP-1s like Novo’s Ozempic will be less than $150 out of pocket. Dr. Mehmet Oz, the Centers for Medicare & Medicaid Services administrator, interjected to say that those deals have not yet been finalized.

The Trump administration has been negotiating with drugmakers to bring down drug prices in the US. Currently, the popular weight-loss drugs made by Lilly and Novo cost between $300 and $500 a month out of pocket through the drugmakers’ direct-to-consumer platforms.

Hims & Hers, which sells compounded versions of Novo's weight loss shot, also fell on Friday. A monthly dose of Hims' compounded GLP-1 is about $200 a month, more than what Trump suggests the brand-name version could cost soon.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.